Tri Vo
Family Medicine · El Monte, CANPI 1407907744
Payments from drug & device makers
Across 449 payments — averaging $41.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Gilead$2K
- Amarin Pharma, Inc.$2K
- Johnson & Johnson$1K
- Abbott$1K
- Boehringer Ingelheim$798
- plus $5K from 20 others
What the payments were for
- Food & beverage$18,449100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 176 | $7,226 |
| Gilead | 14 | $1,653 |
| Amarin Pharma, Inc. | 34 | $1,580 |
| Johnson & Johnson | 34 | $1,255 |
| Abbott | 28 | $1,163 |
| Boehringer Ingelheim | 30 | $798 |
| Novartis | 46 | $703 |
| Amgen | 7 | $648 |
| AbbVie(2 entities) | 10 | $588 |
| Lilly USA, LLC | 15 | $507 |
| Bayer | 10 | $323 |
| Regeneron Healthcare Solutions, Inc. | 2 | $240 |
| Lexicon Pharmaceuticals, Inc. | 7 | $237 |
| GSK | 10 | $227 |
| Sanofi-aventis U.S. LLC | 10 | $172 |
| Alkermes, Inc. | 1 | $130 |
| Neurocrine Biosciences, Inc. | 1 | $128 |
| Theratechnologies Inc. | 1 | $125 |
| Pfizer | 1 | $125 |
| Novo Nordisk | 1 | $119 |
| Intercept Pharmaceuticals, Inc. | 1 | $117 |
| Merck | 1 | $100 |
| Esperion Therapeutics, Inc. | 1 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $86 |
| Astellas Pharma US Inc | 5 | $62 |
| Sun Pharmaceutical Industries Inc. | 2 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,449 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 28 | $34,631 |
| Xigduo XrDapaglifloz Propaned/Metformin | 29 | $30,316 |
| VemlidyTenofovir Alafenamide | 11 | $15,242 |
| VascepaIcosapent Ethyl | 17 | $9,736 |
| XareltoRivaroxaban | 16 | $9,660 |
| Atorvastatin Calcium | 90 | $1,169 |
| Metformin Hcl | 53 | $747 |
| Pioglitazone Hcl | 38 | $574 |
| Gabapentin | 22 | $485 |
| Famotidine | 24 | $431 |
| Azelastine Hcl | 21 | $311 |
| Triamcinolone Acetonide | 48 | $305 |
| Losartan Potassium | 14 | $302 |
| Glimepiride | 11 | $288 |
| Allopurinol | 16 | $280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $323 | $34,63128 claims |
| GileadVemlidy | $1,653 | $15,24211 claims |
| Johnson & JohnsonXarelto | $1,255 | $9,66016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in El Monte
- Sreedhar ChavaEl Monte$1.3M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.